Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Transderm Scop Generic Name & Formulations
Legal Class
Rx
General Description
Scopolamine 1.5mg (delivers approximately 1mg over 3 days); transdermal patch.
Pharmacological Class
Anticholinergic.
How Supplied
Patches—4, 10, 24
Manufacturer
Mechanism of Action
Scopolamine, a belladonna alkaloid, is an anticholinergic. Scopolamine acts: i) as a competitive inhibitor at postganglionic muscarinic receptor sites of the parasympathetic nervous system, and ii) on smooth muscles that respond to acetylcholine but lack cholinergic innervation. It has been suggested that scopolamine acts in the central nervous system (CNS) by blocking cholinergic transmission from the vestibular nuclei to higher centers in the CNS and from the reticular formation to the vomiting center.
Transderm Scop Indications
Indications
Prevention of motion sickness and post-op nausea/vomiting (PONV).
Transderm Scop Dosage and Administration
Adult
Apply to dry skin behind ear; do not cut patch. Motion sickness: 1 patch at least 4hrs before required effect; remove after 72hrs. Apply a new patch if therapy is required >3 days. PONV (for surgeries except cesarean): 1 patch evening before surgery. Remove 24hrs after surgery.
Children
Not established.
Transderm Scop Contraindications
Contraindications
Acute closure glaucoma. Allergy to belladonna alkaloids.
Transderm Scop Boxed Warnings
Not Applicable
Transderm Scop Warnings/Precautions
Warnings/Precautions
Wash hands and skin after use; avoid eyes. Monitor IOP in those with glaucoma. Psychosis. Monitor for new or worsening psychiatric symptoms; discontinue if psychiatric reactions or cognitive impairment occur. GI or urinary tract obstruction. Seizures. MRI skin burns; remove prior to imaging. Renal or hepatic impairment. Elderly. Pregnancy (avoid if severe preeclampsia). Nursing mothers.
Transderm Scop Pharmacokinetics
Absorption
Circulating plasma concentrations are detected within 4hrs with peak concentrations obtained (on average) within 24 hours.
Distribution
The distribution of scopolamine is not well characterized. It crosses the placenta and the blood brain barrier and may be reversibly bound to plasma proteins.
Elimination
Renal. Half-life: 9.5 hours.
Transderm Scop Interactions
Interactions
Alcohol, other CNS depressants potentiate CNS depression. Additive anticholinergic effects with other anticholinergics, antihistamines (eg, meclizine), tricyclic antidepressants; monitor. May affect absorption of other drugs. Interferes with gastric secretion test; discontinue 10 days prior to testing.
Transderm Scop Adverse Reactions
Adverse Reactions
Dry mouth, drowsiness, blurred vision, dilation of the pupils, visual impairment, dizziness, somnolence, agitation, confusion, mydriasis, pharyngitis; difficult urination (discontinue if occurs), withdrawal symptoms may occur if used for >3 days.
Transderm Scop Clinical Trials
See Literature
Transderm Scop Note
Not Applicable
Transderm Scop Patient Counseling
See Literature
